CAR T-cell

Oncology landscape stays hot for dealmakers

Intense competition for dealmaking in oncology “shows no sign of abating.” That’s the key takeaway from recent analysis developed by Jamie Munro and Helen Dowden, of Clarivate Analytics. Their article, “Oncology dealmaking trends”, was featured in the Biopharma Dealmakers supplement to Nature Biotechnology and Nature Reviews: Drug Discovery. Munro, global practice leader, portfolio and licensing, […]

Immuno-oncology spotlight on diverse therapeutic classes

Immune checkpoint inhibitors, such as the multi-billion-dollar drugs Keytruda and Opdivo, have dominated the immuno-oncology landscape in recent years (see Figure 1), but are not the only classes on the market or in development. T-cell engager therapeutics, oncolytic virus therapy and adoptive T-cell therapies were among the promising technologies covered at the fourth annual Immuno-Oncology […]

CAR T-cell gene therapies enter the U.S. market

Ground-breaking anti-cancer immunotherapy Novartis and the University of Pennsylvania’s anti-cancer chimeric antigen receptor (CAR) T-cell therapy Kymriah has become the first ever gene-modified therapy approved in the U.S. The therapy takes the patient’s own T cells, engineers them to express a receptor that binds to the B-cell blood cancer marker CD19, and then re-infuses them […]